Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21482701 | 0.83 | KMT2A (0.49) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2184519 | 0.83 | SMN1; SMN2 (0.64) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6641796 | 0.82 | KMT2A (0.48) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL14660006 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL27536605 | 0.81 | CYP1A2 (0.64) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL20993618 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL75590 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL20993624 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL11713277 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2390792 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118851894-A | Preparation method of 4-halogenated-2-trifluoromethyl acetophenone | 帕潘纳(北京)科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| WO-2015088885-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103096718-A | Soluble guanylate cyclase activators | MERCK SHARP & DOHME | 2013-05-08 | — | — | CN | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| EP-2274296-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| EP-2274296-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | CYP1A2 1320/4885CYP3A4 2660/4885KMT2A 4728/4885 |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | PRUNE1, PRDX5, PDCD11 | CYP1A2 2202/4885CYP3A4 1953/4885KMT2A 3191/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP1A2 190/4885CYP3A4 387/4885KMT2A 2547/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | CYP1A2 1747/4885CYP3A4 2982/4885KMT2A 3203/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CYP1A2 3591/4885CYP3A4 4243/4885KMT2A 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.